Functional characterization of the human biglycan 5'-flanking DNA and binding of the transcription factor c-Krox
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Functional characterization of the human biglycan 5'-flanking DNA and binding of the transcription factor c-Krox. / Heegaard, Anne-Marie; Gehron Robey, P; Vogel, W; Just, W; Widom, R L; Schøller, J; Fisher, L W; Young, M F.
I: Journal of Bone and Mineral Research, Bind 12, Nr. 12, 1997, s. 2050-60.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Functional characterization of the human biglycan 5'-flanking DNA and binding of the transcription factor c-Krox
AU - Heegaard, Anne-Marie
AU - Gehron Robey, P
AU - Vogel, W
AU - Just, W
AU - Widom, R L
AU - Schøller, J
AU - Fisher, L W
AU - Young, M F
PY - 1997
Y1 - 1997
N2 - The transcriptional regulation of human biglycan expression under normal and pathological conditions was studied. The 5'-flanking regions of the human and mouse genes were isolated and analyzed; the two promoter regions share 81% identity. Both promoters are without a TATA and CAT box and contain multiple Sp1 sites. Human dermal fibroblasts were transiently transfected with progressive deletional human biglycan 5'-flanking DNA-CAT constructs, and a significant variation in activity among the individual constructs was found. A small deletion in several cases caused a more than 2-fold increase or decrease in promoter activity, thereby mapping the target sites for repressors or activators. Human biglycan expression is reduced in females with Ullrich-Turner syndrome (45,X) and increased in individuals with supernumerary sex chromosomes, and it has been speculated that biglycan plays a role in the short stature phenotype of Turner syndrome. Analysis of the transcriptional regulation of biglycan in individuals with sex chromosome anomalies showed that a -262 to -218 region of the biglycan promoter was differentially regulated. This region was extensively analyzed by DNAse footprinting and electrophoretic mobility shift assays, and a putative binding site for the transcription factor c-Krox was discovered. The binding of c-Krox to a site located at approximately -248 to -230 in the human biglycan promoter was confirmed by using extracts from COS cells expressing recombinant human c-Krox. The expression of c-Krox in bone was then examined by reverse-transcribed polymerase chain reaction and Northern blotting analysis; an approximately 3.4 kb transcript was detected in primary osteoblastic cells, in MG-63 cells, and in human bone marrow stromal cells. This is the first detection of c-Krox in bone cells, and it suggests that c-Krox, like another member of the Krox family, Krox-20, might play a regulatory role in bone.
AB - The transcriptional regulation of human biglycan expression under normal and pathological conditions was studied. The 5'-flanking regions of the human and mouse genes were isolated and analyzed; the two promoter regions share 81% identity. Both promoters are without a TATA and CAT box and contain multiple Sp1 sites. Human dermal fibroblasts were transiently transfected with progressive deletional human biglycan 5'-flanking DNA-CAT constructs, and a significant variation in activity among the individual constructs was found. A small deletion in several cases caused a more than 2-fold increase or decrease in promoter activity, thereby mapping the target sites for repressors or activators. Human biglycan expression is reduced in females with Ullrich-Turner syndrome (45,X) and increased in individuals with supernumerary sex chromosomes, and it has been speculated that biglycan plays a role in the short stature phenotype of Turner syndrome. Analysis of the transcriptional regulation of biglycan in individuals with sex chromosome anomalies showed that a -262 to -218 region of the biglycan promoter was differentially regulated. This region was extensively analyzed by DNAse footprinting and electrophoretic mobility shift assays, and a putative binding site for the transcription factor c-Krox was discovered. The binding of c-Krox to a site located at approximately -248 to -230 in the human biglycan promoter was confirmed by using extracts from COS cells expressing recombinant human c-Krox. The expression of c-Krox in bone was then examined by reverse-transcribed polymerase chain reaction and Northern blotting analysis; an approximately 3.4 kb transcript was detected in primary osteoblastic cells, in MG-63 cells, and in human bone marrow stromal cells. This is the first detection of c-Krox in bone cells, and it suggests that c-Krox, like another member of the Krox family, Krox-20, might play a regulatory role in bone.
KW - Animals
KW - Base Sequence
KW - Biglycan
KW - Cell Line
KW - Cloning, Molecular
KW - DNA
KW - DNA Footprinting
KW - DNA-Binding Proteins
KW - Electrophoresis, Polyacrylamide Gel
KW - Extracellular Matrix Proteins
KW - Fibroblasts
KW - Humans
KW - Mice
KW - Molecular Sequence Data
KW - Osteoblasts
KW - Protein Binding
KW - Proteoglycans
KW - RNA, Messenger
KW - Sequence Homology, Nucleic Acid
KW - Sex Chromosome Aberrations
KW - Transcription Factors
KW - Transfection
KW - Zinc Fingers
U2 - 10.1359/jbmr.1997.12.12.2050
DO - 10.1359/jbmr.1997.12.12.2050
M3 - Journal article
C2 - 9421237
VL - 12
SP - 2050
EP - 2060
JO - Journal of Bone and Mineral Research
JF - Journal of Bone and Mineral Research
SN - 0884-0431
IS - 12
ER -
ID: 38426694